JP3040121B2
(ja)
*
|
1988-01-12 |
2000-05-08 |
ジェネンテク,インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
US6884418B1
(en)
*
|
1989-08-04 |
2005-04-26 |
Berlex Laboratories, Inc. |
Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
|
CA2095141A1
(en)
*
|
1990-11-05 |
1992-05-06 |
Ingegerd Hellstrom |
Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
KR20010071271A
(ko)
|
1998-05-15 |
2001-07-28 |
존 비. 랜디스 |
방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
US6824997B1
(en)
*
|
1998-09-18 |
2004-11-30 |
Binax, Inc. |
Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
|
US20080096236A1
(en)
*
|
1998-08-25 |
2008-04-24 |
Binax, Inc. |
Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
|
US9134303B1
(en)
|
1998-08-25 |
2015-09-15 |
Alere Scarborough, Inc. |
ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
|
HUP0201480A3
(en)
*
|
1999-05-14 |
2009-03-30 |
Imclone Systems Inc |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
TWI269654B
(en)
|
1999-09-28 |
2007-01-01 |
Baxter Healthcare Sa |
N-substituted indole-3-glyoxylamide compounds having anti-tumor action
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
AU2001264946A1
(en)
*
|
2000-05-24 |
2001-12-03 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
EP1170011A1
(en)
*
|
2000-07-06 |
2002-01-09 |
Boehringer Ingelheim International GmbH |
Novel use of inhibitors of the epidermal growth factor receptor
|
JP2004527456A
(ja)
*
|
2000-08-09 |
2004-09-09 |
イムクローン システムズ インコーポレイティド |
Egf受容体拮抗剤による過増殖性の疾患の治療
|
KR100589032B1
(ko)
*
|
2000-10-20 |
2006-06-14 |
에자이 가부시키가이샤 |
질소 함유 방향환 유도체
|
US7906492B2
(en)
*
|
2001-01-16 |
2011-03-15 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US7507724B2
(en)
*
|
2001-01-16 |
2009-03-24 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
PL363311A1
(en)
|
2001-04-24 |
2004-11-15 |
Merck Patent Gmbh |
Combination therapy using anti-angiogenic agents and tnfalpha
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
PT2163256E
(pt)
*
|
2001-05-11 |
2015-11-20 |
Ludwig Inst For Cancer Res Ltd |
Proteínas de ligação específica e suas utilizações
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
JP4298498B2
(ja)
*
|
2001-06-13 |
2009-07-22 |
ゲンマブ エー/エス |
上皮成長因子受容体(egfr)に対するヒトモノクローナル抗体
|
US20040242851A1
(en)
*
|
2001-06-26 |
2004-12-02 |
Zhenping Zhu |
Bispecific antibodies that bind to vegf receptors
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
AU2002319402B2
(en)
*
|
2001-06-28 |
2008-09-11 |
Domantis Limited |
Dual-specific ligand and its use
|
DE10133394A1
(de)
*
|
2001-07-13 |
2003-01-30 |
Merck Patent Gmbh |
Flüssige Formulierung enthaltend Cetuximab
|
ES2362931T3
(es)
|
2002-03-04 |
2011-07-15 |
Imclone Llc |
Anticuerpos humanos específicos contra kdr y usos de los mismos.
|
US20050119303A1
(en)
*
|
2002-03-05 |
2005-06-02 |
Eisai Co., Ltd |
Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with an angiogenesis inhibitor
|
IL165256A0
(en)
*
|
2002-05-24 |
2005-12-18 |
Schering Corp |
Neutralizing human anti-igfr antibody
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
AU2003244817B2
(en)
*
|
2002-06-28 |
2010-08-26 |
Domantis Limited |
Antigen-binding immunoglobulin single variable domains and dual-specific constructs
|
RU2349340C2
(ru)
*
|
2002-10-10 |
2009-03-20 |
Мерк Патент Гмбх |
Биспецифические антитела к erb-b и их применение для лечения опухолей
|
WO2005044858A1
(en)
|
2003-11-07 |
2005-05-19 |
Ablynx N.V. |
Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
|
US20040147428A1
(en)
*
|
2002-11-15 |
2004-07-29 |
Pluenneke John D. |
Methods of treatment using an inhibitor of epidermal growth factor receptor
|
US8505468B2
(en)
*
|
2002-11-19 |
2013-08-13 |
Sharp Kabushiki Kaisha |
Substrate accommodating tray
|
AU2003290330A1
(en)
*
|
2002-12-27 |
2004-07-22 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
ATE508747T1
(de)
|
2003-03-10 |
2011-05-15 |
Eisai R&D Man Co Ltd |
C-kit kinase-hemmer
|
EP1622941A2
(en)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
US7425328B2
(en)
*
|
2003-04-22 |
2008-09-16 |
Purdue Pharma L.P. |
Tissue factor antibodies and uses thereof
|
CA2524305C
(en)
|
2003-05-01 |
2015-12-08 |
Imclone Systems Incorporated |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
CN101966338A
(zh)
|
2003-06-09 |
2011-02-09 |
塞缪尔·瓦克萨尔 |
用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
|
CA2530172A1
(en)
|
2003-06-27 |
2005-02-10 |
Abgenix, Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
EP1683785B1
(en)
*
|
2003-11-11 |
2013-10-16 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for producing the same
|
AR046639A1
(es)
*
|
2003-11-21 |
2005-12-14 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti- igfr1
|
DE10355904A1
(de)
*
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
US7767792B2
(en)
*
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
US7598350B2
(en)
*
|
2004-03-19 |
2009-10-06 |
Imclone Llc |
Human anti-epidermal growth factor receptor antibody
|
UA88008C2
(en)
|
2004-04-09 |
2009-09-10 |
Чугей Сейяку Кабусики Кайся |
Water-soluble prodrugs
|
AU2005265163B2
(en)
*
|
2004-06-18 |
2009-10-01 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
US8772269B2
(en)
*
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
AU2005283422C1
(en)
|
2004-09-17 |
2017-02-02 |
Eisai R & D Management Co., Ltd. |
Medicinal composition
|
WO2006042313A2
(en)
*
|
2004-10-12 |
2006-04-20 |
Imclone Systems Incorporated |
Egfr antagonist in treatment of fluid accumulation
|
JP2008519757A
(ja)
*
|
2004-11-12 |
2008-06-12 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
抗egfr抗体の固形物
|
DK1859793T3
(da)
*
|
2005-02-28 |
2011-08-01 |
Eisai R&D Man Co Ltd |
Hidtil ukendt kombinationsanvendelse af en sulfonamidforbindelse i behandlingen af cancer
|
MX2007012896A
(es)
*
|
2005-04-15 |
2007-12-10 |
Schering Corp |
Metodos y composiciones para tratamiento o prevencion de cancer.
|
US20090214562A1
(en)
*
|
2005-05-03 |
2009-08-27 |
Karel Steven J |
Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
|
MX2007016306A
(es)
|
2005-06-15 |
2008-03-07 |
Schering Corp |
Formulaciones de anticuerpo anti-igf1r.
|
ES2452115T3
(es)
|
2005-06-17 |
2014-03-31 |
Imclone Llc |
Un anticuerpo anti-PDGFRalfa para su uso en el tratamiento de cáncer de huesos metastásico
|
JP2007039346A
(ja)
*
|
2005-08-01 |
2007-02-15 |
Yokohama Kokusai Bio Kenkyusho:Kk |
腫瘍特異的抗体と結合したタキソイド誘導体及びその製造方法
|
WO2007015569A1
(ja)
*
|
2005-08-01 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を予測する方法
|
EP2281901B1
(en)
|
2005-08-02 |
2013-11-27 |
Eisai R&D Management Co., Ltd. |
Anti-tumour pharmaceutical composition with angiogenesis inhibitors
|
TW200744603A
(en)
|
2005-08-22 |
2007-12-16 |
Chugai Pharmaceutical Co Ltd |
Novel anticancer concomitant drug
|
EP1938842A4
(en)
*
|
2005-09-01 |
2013-01-09 |
Eisai R&D Man Co Ltd |
METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
|
BRPI0617236A2
(pt)
|
2005-10-11 |
2011-07-19 |
Merck Patent Gmbh |
modulação da expressão de quimiocina, dependente de egfr, e influência sobre a terapia e diagnóstico de tumores e efeitos colaterais da mesma
|
AU2006309551B2
(en)
|
2005-11-07 |
2012-04-19 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
EP1948180B1
(en)
*
|
2005-11-11 |
2013-03-13 |
Boehringer Ingelheim International GmbH |
Combination treatment of cancer comprising egfr/her2 inhibitors
|
EP3173084B1
(en)
|
2005-11-11 |
2019-10-23 |
Boehringer Ingelheim International GmbH |
Quinazoline derivatives for the treatment of cancer diseases
|
EP1964837A4
(en)
*
|
2005-11-22 |
2010-12-22 |
Eisai R&D Man Co Ltd |
Antitumor agent against multiple myeloma
|
WO2007063308A2
(en)
*
|
2005-12-01 |
2007-06-07 |
Domantis Limited |
Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
|
KR20080110987A
(ko)
|
2006-01-04 |
2008-12-22 |
메르크 파텐트 게엠베하 |
항-egfr 및 항-her2 항체를 이용하는 조합 요법
|
US8323644B2
(en)
*
|
2006-01-17 |
2012-12-04 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
EP2015775B1
(en)
|
2006-05-03 |
2011-06-01 |
Bayer Schering Pharma Aktiengesellschaft |
Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
|
CN101443009A
(zh)
*
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
JPWO2008001956A1
(ja)
*
|
2006-06-29 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
肝線維症治療剤
|
CA2655997A1
(en)
|
2006-06-30 |
2008-01-10 |
Schering Corporation |
Igfbp2 biomarker
|
WO2008026748A1
(fr)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
CN110613845A
(zh)
*
|
2007-01-25 |
2019-12-27 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
US8962655B2
(en)
|
2007-01-29 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
MX2009008909A
(es)
*
|
2007-03-01 |
2009-08-28 |
Symphogen As |
Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
|
SG182170A1
(en)
*
|
2007-06-06 |
2012-07-30 |
Domantis Ltd |
Polypeptides, antibody variable domains and antagonists
|
KR100883430B1
(ko)
*
|
2007-06-13 |
2009-02-12 |
한국생명공학연구원 |
혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
|
WO2008154927A1
(en)
*
|
2007-06-21 |
2008-12-24 |
Genmab A/S |
Novel methods for treating egfr-associated tumors
|
US9283276B2
(en)
*
|
2007-08-14 |
2016-03-15 |
Ludwig Institute For Cancer Research Ltd. |
Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
|
EP3492488A1
(en)
|
2007-08-22 |
2019-06-05 |
The Regents of The University of California |
Activatable binding polypeptides and methods of identification and use thereof
|
EP2205249B1
(en)
|
2007-09-28 |
2018-11-07 |
Intrexon Corporation |
Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
|
CA2702637A1
(en)
*
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
JP5638244B2
(ja)
|
2007-11-09 |
2014-12-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質と抗腫瘍性白金錯体との併用
|
CA2713930A1
(en)
*
|
2008-01-29 |
2009-08-06 |
Eisai R & D Management Co., Ltd. |
Combined use of angiogenesis inhibitor and taxane
|
MX2010008786A
(es)
|
2008-02-11 |
2010-12-01 |
Curetech Ltd |
Anticuerpos monoclonales para tratamiento de tumores.
|
CN102014913A
(zh)
*
|
2008-03-06 |
2011-04-13 |
健泰科生物技术公司 |
C-met和egfr拮抗剂的联合疗法
|
AR071891A1
(es)
*
|
2008-05-30 |
2010-07-21 |
Imclone Llc |
Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
|
WO2010022736A2
(en)
|
2008-08-29 |
2010-03-04 |
Symphogen A/S |
Recombinant anti-epidermal growth factor receptor antibody compositions
|
EP3216874A1
(en)
*
|
2008-09-05 |
2017-09-13 |
TOMA Biosciences, Inc. |
Methods for stratifying and annotating cancer drug treatment options
|
AU2010203353B2
(en)
|
2009-01-12 |
2016-06-16 |
Cytomx Therapeutics, Inc |
Modified antibody compositions, methods of making and using thereof
|
EP2398494A4
(en)
|
2009-02-23 |
2015-10-28 |
Cytomx Therapeutics Inc |
Proproteins and their methods of use
|
CN102356092B
(zh)
*
|
2009-03-20 |
2014-11-05 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
US9545381B2
(en)
|
2009-07-06 |
2017-01-17 |
Boehringer Ingelheim International Gmbh |
Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
|
EP2461870B1
(en)
|
2009-07-22 |
2017-09-06 |
Biothera, Inc. |
Composition comprising beta-glucan and an egf-r antibody or an egf-r antagonist for use in the treatment of kras-mutated tumors
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
EP2491032B1
(en)
|
2009-10-23 |
2014-04-16 |
Eli Lilly and Company |
Akt inhibitors
|
WO2011107664A1
(en)
|
2010-03-04 |
2011-09-09 |
Hospital District Of Southwest Finland |
Method for selecting patients for treatment with an egfr inhibitor
|
EP2371369A1
(en)
|
2010-04-01 |
2011-10-05 |
Institut Gustave Roussy (IGR) |
EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
|
WO2011156617A2
(en)
|
2010-06-09 |
2011-12-15 |
Aveo Pharmaceuticals, Inc. |
Anti-egfr antibodies
|
US9012458B2
(en)
|
2010-06-25 |
2015-04-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
US9464136B2
(en)
|
2010-08-20 |
2016-10-11 |
Massachusetts Institute Of Technology |
Antibody-based constructs directed against tyrosine kinase receptors
|
KR20130113447A
(ko)
|
2010-09-24 |
2013-10-15 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화
|
KR20140075639A
(ko)
|
2010-10-27 |
2014-06-19 |
더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 |
암 치료법을 위한 e-카드헤린의 가용성 세포외 도메인의 표적화 조성물 및 관련 방법
|
US9238690B2
(en)
|
2010-10-29 |
2016-01-19 |
Immunogen, Inc. |
Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
|
EA201390472A1
(ru)
|
2010-10-29 |
2014-02-28 |
Иммьюноджен, Инк. |
Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
|
WO2012068487A1
(en)
|
2010-11-18 |
2012-05-24 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
|
US8628773B2
(en)
|
2011-04-07 |
2014-01-14 |
Amgen Inc. |
Antigen binding proteins
|
EP2700403B1
(en)
|
2011-04-18 |
2015-11-25 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
WO2012166899A2
(en)
|
2011-06-03 |
2012-12-06 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
MX360741B
(es)
|
2011-10-28 |
2018-11-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Constructos de polipéptidos y sus usos.
|
US9233171B2
(en)
|
2011-11-21 |
2016-01-12 |
Immunogen, Inc. |
Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate
|
EP2879712B1
(en)
|
2012-07-31 |
2018-04-25 |
Crown Bioscience, Inc. (Taicang) |
Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug
|
EA028420B1
(ru)
|
2012-08-07 |
2017-11-30 |
Новартис Аг |
Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа
|
CA2885340C
(en)
|
2012-10-12 |
2016-11-08 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2014095088A1
(en)
|
2012-12-21 |
2014-06-26 |
Sykehuset Sørlandet Hf |
Egfr targeted therapy of neurological disorders and pain
|
KR20150098605A
(ko)
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
EP3594231A1
(en)
|
2013-02-13 |
2020-01-15 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Highly galactosylated anti-tnf-alpha antibodies and uses thereof
|
EP2956003A2
(en)
|
2013-02-13 |
2015-12-23 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Proteins with modified glycosylation and methods of production thereof
|
KR102066319B1
(ko)
|
2013-03-13 |
2020-01-14 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨쥬게이트
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
SG11201508923VA
(en)
|
2013-04-29 |
2015-11-27 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
|
WO2014178078A2
(en)
*
|
2013-04-30 |
2014-11-06 |
Intas Boipharmaceuticals Limited |
Novel cloning, expression & purification method for the preparation of ranibizumab
|
SG11201509278XA
(en)
|
2013-05-14 |
2015-12-30 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
WO2015038811A2
(en)
|
2013-09-11 |
2015-03-19 |
Arsia Therapeutics, Inc. |
Liquid protein formulations containing ionic liquids
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
PL3524595T3
(pl)
|
2014-08-28 |
2022-10-31 |
Eisai R&D Management Co., Ltd. |
Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
JP6716577B2
(ja)
|
2014-10-01 |
2020-07-01 |
イーグル・バイオロジクス・インコーポレイテッドEagle Biologics, Inc. |
粘度低下物質を含有する、多糖および核酸の調合薬
|
US10385380B2
(en)
|
2014-10-02 |
2019-08-20 |
The Regents Of The University Of California |
Personalized protease assay to measure protease activity in neoplasms
|
JP6656243B2
(ja)
|
2014-10-28 |
2020-03-04 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
細胞表面での非共有結合Fcドメイン含有タンパク質ディスプレイの方法及びそのスクリーニング方法
|
MX2017005481A
(es)
|
2014-10-29 |
2017-10-26 |
Teva Pharmaceuticals Australia Pty Ltd |
Variantes de interferon a2b.
|
PT3227311T
(pt)
|
2014-12-05 |
2022-02-23 |
Xyphos Biosciences Inc |
Fragmentos variáveis inseríveis de anticorpos e domínios a1-a2 modificados de ligandos de nkg2d
|
SI3263106T1
(sl)
|
2015-02-25 |
2024-02-29 |
Eisai R&D Management Co., Ltd. |
Postopek zatiranja grenkobe derivata kinolina
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
MX2017015896A
(es)
|
2015-06-16 |
2018-08-09 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
CN105237638A
(zh)
*
|
2015-10-26 |
2016-01-13 |
无锡傲锐东源生物科技有限公司 |
抗egfr蛋白单克隆抗体杂交瘤细胞及其产生的抗egfr单克隆抗体和应用
|
CN109563166B
(zh)
|
2016-04-28 |
2022-12-20 |
拜奥穆尼克斯制药 |
靶向egfr和her2的双特异性抗体
|
KR102439911B1
(ko)
|
2016-06-03 |
2022-09-05 |
어레이 바이오파마 인크. |
제약학적 복합제제
|
KR20190019091A
(ko)
|
2016-06-24 |
2019-02-26 |
사이포스 바이오사이언시스 인코포레이티드 |
항체의 삽입가능 가변 단편 및 nkg2d 리간드의 변형된 a1-a2 도메인
|
WO2018069289A1
(en)
|
2016-10-11 |
2018-04-19 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
CN106800599B
(zh)
*
|
2016-12-05 |
2021-03-23 |
中国人民解放军第二军医大学 |
抗人EGFR和Notch多特异性抗体、其制备方法及用途
|
JP6581320B2
(ja)
|
2017-02-08 |
2019-09-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|
EP3624846A1
(en)
|
2017-05-16 |
2020-03-25 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
CA3019207A1
(en)
|
2017-09-28 |
2019-03-28 |
The Governing Council Of The University Of Toronto |
Methods and compositions for inhibiting mutant egfr signaling
|
US20220111065A1
(en)
|
2018-05-23 |
2022-04-14 |
Adc Therapeutics Sa |
Molecular adjuvant
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
US20220016277A1
(en)
|
2018-11-20 |
2022-01-20 |
Cornell University |
Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
|
WO2020200944A1
(en)
|
2019-03-29 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Method for generating avid-binding multispecific antibodies
|
WO2020225552A1
(en)
|
2019-05-06 |
2020-11-12 |
Medimmune Limited |
Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
WO2022211051A1
(ja)
|
2021-03-31 |
2022-10-06 |
日本メジフィジックス株式会社 |
抗egfr抗体の放射性複合体、及び、放射性医薬
|
CN117500523A
(zh)
|
2021-06-14 |
2024-02-02 |
免疫分子中心 |
针对表皮生长因子受体的单克隆抗体治疗患有低氧血症型急性呼吸衰竭的患者的用途
|
AU2022310862A1
(en)
|
2021-07-14 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
WO2023166098A1
(en)
|
2022-03-02 |
2023-09-07 |
Biomunex Pharmaceuticals |
Bispecific antibodies binding to her-3 and to either her-2 or egfr
|
WO2023196996A2
(en)
|
2022-04-08 |
2023-10-12 |
2Seventy Bio, Inc. |
Multipartite receptor and signaling complexes
|